Archive · 2 Jun 2025
Apollo Hospitals: Analysts React to Q4 Results with Revised Targets
Imagine Apollo Hospitals is like a big company that runs many hospitals and pharmacies.
After their latest report, experts are talking about how well they are doing.
Some experts think the company will do great, pointing to new hospital beds and online services.
Others think the company's doing okay, and some experts even lowered their price predictions for the company's shares, even though they still like the company's potential to grow.
They're expanding, but not everything is perfect, and it might take a little time for all the new things to start making a lot of money.
Analysts reacted to Apollo Hospitals' Q4 earnings, released after market hours.
Morgan Stanley lowered its price target but maintains an 'Overweight' rating.
Citi and Goldman Sachs have 'Buy' ratings on the stock.
Nomura has a 'Neutral' rating.
Key growth drivers include hospital expansion, HealthCo growth, and AHLL development.
- Who
- Analysts from Nomura, Morgan Stanley, Citi, and Goldman Sachs, along with investors and stakeholders, are assessing Apollo Hospitals.
- What
- Analysts reviewed the financial results of Apollo Hospitals Enterprises Ltd. after the announcement of their Q4 earnings.
- When
- The analysis is based on the Q4 results of Apollo Hospitals, announced after market hours on a Friday.
- Where
- Apollo Hospitals operates in the healthcare sector.
- Why
- Analysts are discussing the company's Q4 results and future prospects.
Neutral Rating
Buy Ratings
Analyst Ratings
Neutral Rating
Nomura has a 'Neutral' rating, noting the Q4 revenue was in line with expectations while EBITDA was slightly above estimates, but lower than consensus.
Buy Ratings
Citi, Morgan Stanley, and Goldman Sachs maintain a 'Buy' rating, highlighting potential for strong shareholder returns and positive growth.
- Share Price (Friday closing)
- ₹6,886
- Nomura Rating
- Neutral
- Nomura Price Target
- ₹6,856
- Morgan Stanley Rating
- Buy
- Morgan Stanley Price Target
- ₹8,058
- Citi Rating
- Buy
- Citi Price Target
- ₹8,260
- Goldman Sachs Rating
- Buy
- Goldman Sachs Price Target
- ₹7,850